GGHC
EPZM

Gilder Gagnon Howe & Co’s Epizyme, Inc EPZM Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-140,319
Closed -$2.65M – 289
2014
Q4 		$2.65M Sell
140,319
-429,820
-75% -$10M 0.04% 171
2014
Q3 		$15.5M Sell
570,139
-5,498
-1% -$171K 0.22% 85
2014
Q2 		$17.9M Sell
575,637
-850
-0.1% -$20K 0.24% 90
2014
Q1 		$13.1M Sell
576,487
-5,763
-1% -$175K 0.18% 109
2013
Q4 		$12.1M Buy
582,250
+516,536
+786% +$15M 0.17% 107
2013
Q3 		$2.63M Buy
+65,714
New +$2.23M 0.04% 179

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Gilder Gagnon Howe & Co's EPZM Position: Q1 2015 in Review

Gilder Gagnon Howe & Co sold out of Epizyme, Inc (EPZM) in Q1 2015, closing a stake of 140,319 shares — an estimated $2.65M sold.

Gilder Gagnon Howe & Co first reported a position in EPZM in Q3 2013 and held it in 6 quarters. The position peaked at $17.9M in Q2 2014. 103 funds tracked by Wall St. Rank hold EPZM as of Q1 2015.

  • Gilder Gagnon Howe & Co reported no remaining Epizyme, Inc position as of Q1 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 140,319 Epizyme, Inc shares in Q1 2015, an estimated $2.65M.
  • Gilder Gagnon Howe & Co first reported a position in Epizyme, Inc in Q3 2013 and held it in 6 quarters.
  • Gilder Gagnon Howe & Co's Epizyme, Inc position peaked at $17.9M in Q2 2014.
  • 103 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2015, filed 30 Apr 2015.